SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases

Starting soon

Conditions studied: CRC (Colorectal Cancer), Liver Metastases From Colorectal Primary Cancer

In brief

This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and/or liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures, spheroids, and organoids) to study colorectal cancer stem cells. The main objective is to investigate the role of the lysine methyltransferase SMYD3 in metabolic reprogramming and adaptation to oxidative stress that enable colorectal cancer cells to survive and grow in the liver. Previous work has shown that SMYD3 is overexpressed in colorectal cancer, promotes drug resistance, and regulates key oncogenic pathways, including c-MYC and the AMPK/mTOR axis. By identifying SMYD3-dependent pathways and pharmacologic vulnerabilities in cancer stem cells within liver metastases, this study aims to support the development of new therapeutic strategies that combine SMYD3 inhibitors with approved or experimental agents targeting tumor metabolism and oxidative stress responses

Key facts

Study ID

NCT07497789

Run by

Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

People needed

156

Starts

2026-05-10

Expected to finish

2028-05-10

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Common criteria
• Age ≥ 18 years.
• Availability of residual tumor tissue from the surgical procedure that is not required for diagnostic purposes.
• Signed written informed consent for the use of biological samples for research purposes.
• Cohort/Arm 1 (Colon-rectal tumor resection)
• Patients undergoing surgical resection of colorectal cancer.
• Cohort/Arm 2 (Primary tumor and liver metastases resection) - Patients undergoing surgical resection of the primary colorectal tumor and liver metastases from colorectal carcinoma.
• Cohort/Arm 3 (Liver metastases resection only)
• Patients undergoing surgical resection of liver metastases from colorectal carcinoma previously resected at the primary site.

You may not qualify if…

• Age < 18 years.
• Undergoing surgical intervention for a malignancy other than those specified in the inclusion criteria.
• Lack of signed informed consent

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.